Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 6, 2000, Pages 621-630

  Huitema, Alwin D R ^a,b,c   Mathôt, Ron A A ^a,b   Tibben, Matthijs M ^a,b   Schellens, Jan H M ^a,b   Rodenhuis, Sjoerd ^a,b   Beijnen, Jos H ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; THIOTEPA;

ADULT; ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; FEMALE; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL MODEL; VALIDATION PROCESS;

EID: 0034131494     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.106827     Document Type: Article

References (39)

1. 1. van der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991;21:242-61.
2. 2. Sorensen BT, Strömgren A, Jakobsen P, Theil Nielsen J, Smedegaard Andersen L, Jakobsen A. Renal handling of carboplatin. Cancer Chemother Pharmacol 1992;30: 317-20.
3. 3. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;4:520-8.
4. 4. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;44:5432-8.
5. 5. Sorensen BT, Strömgren A, Jakobsen P, Jakobsen A. Dose-toxicity relationships of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 1991;28:397-401.
6. 6. Jakobsen A, Bertelsen JE, Havsteen H, Jakobsen P, Moeller KA, Nielsen K, et al. Dose-effect study of carboplatin in ovarian cancer: a danish ovarian cancer group study. J Clin Oncol 1997;15:193-8.
7. 7. Duffull SB, Robinson BA. Clinical Pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997;33:161-83.
8. 8. de Lemos ML. Application of the area under the curve of carboplatin in predicting toxicity and efficacy. Cancer Treat Rev 1998;24:407-14.
9. 9. Miyazaki M, Fujiwara Y, Takahashi T, Isobe T, Ohune T, Tsuya T, et al. Limited-sampling models for estimation of the carboplatin area under the curve. Anticancer Res 1997;17:4571-6.
10. 10. Doz F, Urien S, Chatelut E, Michon J, Rubie H, Zucker JM, et al. A limited-sampling model for evaluation of the area under the curve of ultrafilterable carboplatin in children. Cancer Chemother Pharmacol 1998;42:250-4.
11. 11. van Warmerdam LJC, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Limited sampling models for anti-cancer agents. J Cancer Res Clin Oncol 1994;120:427-33.
12. 12. Asai G, Ando Y, Saka H, Ando M, Sugiura S, Sakai S, et al. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model. Eur J Clin Pharmacol 1998;54: 725-7.
13. 13. Sorensen BT, Strömgren A, Jakobsen P, Jakobsen A. A limited sampling method for the estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993;31:324-7.
14. 14. Ghazal-Aswad S, Calvert HA, Newell DR. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 1996;37:419-34.
15. 15. van Warmerdam LJC, Rodenhuis S, van Tellingen O, Maes RAA, Beijnen JH. Validation of a limited sampling model for carboplatin in a high dose chemotherapy combination. Cancer Chemother Pharmacol 1994;35:179-81.
16. 16. Nannan Panday VR, van Warmerdam LJC, Huizing MT, Rodenhuis S, Schellens JHM, Beijnen JH. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen. Cancer Chemother Pharmacol 1999;43:435-8.
17. 17. McLachlan AJ. Sparse drug concentration data analysis using a population approach: a valuable tool in clinical pharmacology. Clin Exp Pharmacol Physiol 1996;23:995-9.
18. 18. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22:447-67.
19. 19. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981;9: 739-56.
20. 20. Duffull SB, Begg EJ, Robinson BA, Deely JJ. A sequential Bayesian algorithm for dose individualization of carboplatin. Cancer Chemother Pharmacol 1997;39:317-26.
21. 21. Guillet P, Monjanel S, Nicoara A, Duffaud F, Lacarelle B, Bagarry-Liegey D, et al. A Bayesian dosing method for carboplatin given by continuous infusion over 120 h. Cancer Chemother Pharmacol 1997;40:143-9.
22. 22. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
23. 23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
24. 24. Jelliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-5.
25. 25. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995;87:573-80.
26. 26. Nannan Panday VR, van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Giaccone G, et al. Carboplatin dosage formulae can generate inaccurate predictions of carboplatin exposure in carboplatin/paclitaxel combination regimens. Clin Drug Invest 1998;15:327-35.
27. 27. van Warmerdam LJC, Rodenhuis S, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996;37:266-70.
28. 28. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 1998;42:307-12.
29. 29. Wright JG, Calvert AH, Highley MS, Roberts JT, MacGill A, Fenwick J, et al. Accurate prediction of renal function for carboplatin dosing [abstract]. Proc Am Assn Cancer Res 1999;40:384.
30. 30. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996;14:1473-83.
31. 31. Huitema ADR, Holtkamp M, Tibben MM, Rodenhuis S, Beijnen JH. Sampling technique from central venous catheters proves to be critical for pharmacokinetic studies. Ther Drug Monit 1999;21:102-4.
32. 32. van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH. Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 1995;351: 1820-4.
33. 33. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles (CA): Biomedical Simulations Resource; 1997.
34. 34. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9:503-12.
35. 35. Merlé Y, Mentré F. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J Pharmacokinet Biopharm 1995;23:101-25.
36. 36. Wakefield J. Bayesian individualization via sampling-based methods. J Pharmacokinet Biopharm 1996;24:103-31.
37. 37. Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 1997;76:1067-71.
38. 38. Fujiwara Y, Takahashi T, Yamakido M, Ohune T, Tsuya T, Egorin MJ. Re: Prediction of carboplatin from standard morphological and biological patient characteristics [letter]. J Natl Cancer Inst 1997;89:261-2.
39. 39. Minami H, Ando Y, Saka H, Shimokata K. Re: Prediction of carboplatin from standard morphological and biological patient characteristics [letter]. J Natl Cancer Inst 1997;89:968-70.